Table 2.

PTCL subtypes associated with miRNA/miRNA-Classifier carrying clinical/molecular relevance.

PTCL subtype	miRNA	Status	Clinical relevance/molecular relevance	Metabolic role	References
PTCL	miR-187	OE	PTCL progression, sensitive to bortezomib	Decreases glucose-stimulated insulin secretion. Role in cancer metabolism unknown	Locke et al. (73) and Yan et al. (66)
AITL	miR-146a	OE	Target TRAF and IRAK1 and negatively regulate the NF-KB pathway	Global regulator of cancer metabolism	Bogusławska et al. (74) and Reddemann et al. (71)
AITL	miR-34a	OE	Inhibits sirtuin-1 (SIRT1), which stimulates the NF-KB pathway	Negative regulator of LDHA expression and glucose metabolism	Reddemann et al. (71) and Zhang et al. (75)
AITL	miR-30b	UE	Targets Delta-like ligand 4 (DLL4) of the NOTCH signaling pathway	Negatively regulated lipid metabolism	Reddemann et al. (71) and Zhang et al. (76)
AITL	miRNA-126-3p	OE	Poor survival outcome, activates RhoA signaling	Role in glycometabolism in cardiovascular diseases, role in cancer metabolism unknown	Lone et al. (77) and Ma et al. (78)
AITL	miR-145-5p	OE	Poor survival outcome	Negatively regulates aerobic glycolysis and its role in mitochondrial metabolism	Hu et al. (79) and Zhao et al. (80)
AITL vs. PTCL GATA3 and PTCL-TBX21	12 miRNAs: miR-125b-5p, miR-497-5p, miR-548ar-5p, miR-145-5p, miR-1469, let-7b-5p, miR-100-5p, miR-603, miR-199a-5p, miR-34a-5p, let-7c-5p, miR-126-3p	OE	Various T-cell receptor signaling, PI2K-Akt signaling, RhoA pathway	x	Lone et al. (77)
ALCL vs. other PTCLs	13 miR signatures: miR-149, miR-210, miR-517c, miR-517a, miR-512-3p, miR-339-5p, miR-339-3p, miR-197, miR-886-5p, miR-886-3p, miR-708, miR-135b, miR-223	OE	No data	x	Liu et al. (81)
ALCL vs. other PTCLs	15 miR signatures: miR-155, miR-455-3p, miR-15a, miR-22, miR-455-5p, miR-660, miR-194, miR-101, miR-1256, miR-100, miR-99a, miR-143, miR-146a, miR-342-5p, miR-150	UE	No data	x	Liu et al. (81)
ALK+ ALCL	miR-13b	OE	Growth promotion by targeting FOXO1	x	Matsuyama et al. (82)
ALK+ ALCL	miR-29a	UE	Modulates apoptosis by inhibiting MCL-1	x	Desjobert et al. (83)
ALK+ ALCL	11 miRNA signatures: miR-26a, miR-29a, miR-29b, miR29c, miR-30a, miR-101, miR-142-3p, miR-142-5p, miR-145, miR-146a, miR-150, miR-343-3p, and miR-451	UE	No data	x	Liu et al. (81)
ALK+ ALCL vs. other PTCLs	5 miR signatures: miR-512-3p, miR-886-5p, miR-886-3p, miR-708, miR-135b	OE	x	x	Liu et al. (81)
	2 miR signatures: miR-155, miR-146a	UE	x	x	Liu et al. (81)
ALK− ALCL vs. other PTCLs	4 miR signatures: miR-191, miR-197, miR-210, miR-512-3p	OE	x	x	Liu et al. (81)
	7 miR signatures: miR-22, miR-143, miR-146a, miR-451, miR-455-3p, miR-455-5p, miR-494	UE	x	x	Liu et al. (81)
ALK− vs. ALK+	4 miRNA classifier: hsa-miR-124, hsa-miR-325, hsa-miR-181a, hsa-miR-618	Classifier	x	x	Laginestra et al. (63)
PTCL-NOS vs. others	20 miRNA signatures: kshv-miR-K12-12-5p, hsa-miR-1290, hsa-miR-5585-3p, hsa-miR-593-3p, hsa-miR-4763-3p, hsa-miR-3196, hsa-miR-4714-5p, hcmv-miR-UL148D, hsa-miR-4485, hsa-miR-4769-3p, hsv1-miR-H17, hsa-miR-1587, hsa-miR-4674, hsa-miR-3913-5p, hsa-miR-614, hsa-miR-224-3p, hsa-miR-4694-3p, hsa-miR-513c-3p, hsa-miR-4677-3p, hsa-miR-218-2-3p	Classifier	x	x	Lin et al. (84)
PTCL-NOS vs. ALK− ALCL	5 miRNA classifier: hsa-miR-155, hsa-miR-199a-5p, hsa-miR-515-3p, hsa-miR-598, hsa-miR-625	Classifier	x	x	Laginestra et al. (63)
PTCL-NOS vs. AITL	8 miRNA classifier: hsa-miR-324-5p, hsa-miR-381, hsa-miR-449a, hsa-miR-487b, hsa-miR-519, hsa-miR-574-3p, hsa-miR-627, hsa-miR-652	Classifier	x	x	Laginestra et al. (63)
PTCL-NOS TBX21 vs. AITL/PTCL-NOS GATA3	5 miRNAs: let-7f-5p, miR-29c-3p, miR-26a-5p, miR-30b-5p, miR-107	OE	x	x	Lone et al. (77)
PTCL-NOS GATA3 vs. AITL/PTCL-NOS TBX21	9 miRNAs: miR-18a-5p,miR-25-3p, miR-106b-5p, miR-181a-5p, miR-93-5p, miR-20a-5p+ miR-20b-5p, miR-423-5p, miR-19b-5p, miR-106-5p+miR-17-5p	OE	x	x	Lone et al. (77)